@entity2791 ( @entity2791 ) may cause @entity101 , @entity2629 , episodes of @entity3126 and @entity712 . Renal artery angioplasty and stenting was performed in 207 @entity1 from 1991 to 1997. Thirty-nine of these @entity1 (19%) underwent renal artery stenting for the control of recurrent episodes of @entity712 and @entity3126 . All @entity1 had angiographic evidence of severe (>70%) bilateral @entity2791 (n = 18) or severe @entity2791 to a solitary functioning kidney (n = 21). Sixteen @entity1 (41%) were male and 23 (59%) were female, mean age 69.9 years (range 50-85 years). Of the 18 @entity1 with bilateral @entity2791 , 12 (66.6%) underwent bilateral stenting. Mean blood pressure decreased from 174/85 +/- 32/23 mmHg to 148/72 +/- 24/14 mmHg (p < 0.001). Mean number of blood pressure medications decreased from 3 +/- 1 to 2.5 +/- 1 (p = 0.006). Twenty-eight @entity1 (71.8%) had improvement in blood pressure control. The mean serum @entity1011 decreased from 3.16 +/- 1.61 to 2.65 +/- 1.87 (p = 0.06). Six of 39 @entity1 (15.4%) used @entity1289 ( @entity1289 ) inhibitors prior to stenting whereas 19 of 39 @entity1 (48.7%) used @entity1289 inhibitors poststenting (p = 0.004). Twenty of 39 @entity1 (51.4%) demonstrated improvement in serum @entity1011 , 10 of 39 @entity1 (25.6%) had stabilization of serum @entity1011 and nine of 39 @entity1 (23%) demonstrated worsening. The number of hospitalizations due to @entity712 in the year preceding renal artery stenting was 2.4 +/- 1.4 and poststenting was 0.3 +/- 0.7 (p < 0.001). The New York Heart Association Functional Class decreased from 2.9 +/- 0.9 prestenting to 1.6 +/- 0.9 poststenting (p < 0.001). Thirty of 39 @entity1 (77%) had no hospitalizations for @entity712 during a mean follow-up period of 21.3 months. Nine @entity1 expired during the course of follow up; eight of the nine @entity1 died within the first year after renal artery stenting. Renal artery stenting decreased the frequency of @entity712 , @entity3126 , and the need for hospitalization in most @entity1 . Blood pressure was markedly improved in the majority of @entity1 with improved or stabilized renal function. Evaluation for @entity2791 is important in @entity101 @entity1 who present with recurrent @entity712 or @entity3126 .

Clinical benefit of renal artery angioplasty with stenting for the control of recurrent and refractory XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity712 :: ('MESH:D006333', 'Disease') :: ['congestive heart failure'] @entity1289 :: ('1636', 'Gene') :: ['angiotensin converting enzyme', 'ACE'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension', 'hypertensive'] @entity3126 :: ('MESH:D011654', 'Disease') :: ['flash pulmonary edema'] @entity2791 :: ('MESH:D012078', 'Disease') :: ['Renal artery stenosis', 'RAS'] @entity2629 :: ('MESH:D053099', 'Disease') :: ['azotemia'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']
@entity712 :: (MESH:D006333,Disease) :: ['congestive heart failure']
